Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome.
about
Treatment of infection due to Pneumocystis cariniiActivities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumoniaPneumocystis carinii dihydrofolate reductase used to screen potential antipneumocystis drugsExpression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductasePotent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolateUridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activityActivity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivoSuccessful treatment of Pneumocystis carinii Pneumonia in mice with benanomicin A (ME1451)Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosisMonodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumoniaLooking beyond highly active antiretroviral therapy: drug-related hepatotoxicity in patients with human immunodeficiency virus infection.Co-infection of Mycobacterium tuberculosis and Pneumocystis jirovecii in the Iranian Patients With Human Immunodeficiency Virus.Recent advances in the diagnosis, treatment, and prevention of Pneumocystis carinii pneumoniaBioavailability of oral trimetrexate in patients with acquired immunodeficiency syndromePneumocystis carinii: A review of an important opportunistic pathogen in AIDSTrimetrexate for Pneumocystis carinii pneumonia in patients with AIDS.Opportunistic infections in HIV-infected patients.Aids and the lung. 6-- Management of respiratory failure in patients with the acquired immune deficiency syndrome and Pneumocystis carinii pneumoniaAIDS and the lung. 7. Treatment of lung disease in patients with the acquired immune deficiency syndrome.Folate during antifolate chemotherapy: what we know... and do not know.Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties.Towards new antifolates targeting eukaryotic opportunistic infectionsSemiquantitative technique for estimating Pneumocystis carinii burden in the lung.N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and toxoplasma gondii dihydrofolate reductase.Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review.Clinical studies of Pneumocystis carinii and relationships to AIDS.Protection and rescue from 2',3'-dideoxypyrimidine nucleoside analog toxicity by hemin in human bone marrow progenitor cellsTreatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.Molecular docking towards drug discovery.Diagnosis of pulmonary disease in human immunodeficiency virus infection role of transbronchial biopsy and bronchoalveolar lavage.Folate antagonists: toward improving the therapeutic index and development of new analogs.Management of Pneumocystis carinii pneumonia in patients with AIDS and other conditions: experience in a Philadelphia University Teaching Hospital.Short course of aerosol pentamidine as treatment of Pneumocystis carinii pneumonia in AIDS.Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole used as First-Line Treatment for Pneumocystis jirovecii Pneumonia.Pneumocystis pneumonia.Vitamins
P2860
Q24519016-DEA16DFE-6084-47E7-9FE9-0358911DFCC7Q28316960-C05567FD-1CEA-46D6-B0BB-7339C48D06FBQ28333677-0DABDEAB-C3B1-47C8-823F-BF156AC6D0D1Q28344866-D9CEA913-0B41-4064-BC2A-60E33614925EQ28360226-8CC91CAB-6A28-4C47-AA0B-855363728D97Q28361147-13290CFD-809C-4716-B5D0-95BB5CFDF679Q28361289-2BE03CC3-9AF8-487B-BD87-52253F757CFFQ28368208-4D8E000B-16B6-4129-AA24-F7DFF85BCEE0Q28378586-07EF49F9-1158-4B2D-9E30-0460A80D0CFDQ28379209-1E5A15C2-0175-40E2-A061-EC48B6D7689EQ34998102-8EB79849-86A6-4580-9921-0C403C29AC0AQ35225474-1849A058-A8F4-4DD4-88F9-3744FF1E8A49Q35251483-5A254A52-BCC0-42BC-8D2C-13A83C99ACD5Q35294525-F09EC5DE-AA09-4434-97A0-015C4A5C9E7FQ35839154-374A3E48-B658-46BF-8BF8-FF7DE7A992EBQ35869078-1DFFE324-647C-4E14-A793-8811BA06C672Q35893214-4B066837-1D55-4A2D-9267-DAD8129EE1DFQ36215653-FCADF8DE-5329-4100-A23A-ECBC76DA9B2EQ36217668-C1B17BF5-8DDC-4A5E-920F-95F00598A496Q36278412-36381973-FAD8-4E55-ACF8-254E18B8B87AQ37097410-CB61F1BD-0882-4FF4-BC7B-6C69033B7307Q37158762-13A4A318-1415-4BB4-B963-DD3E36F65124Q37185256-A118712B-5781-4415-9F92-2756FFC3C1EAQ37451242-25479AB9-C701-4838-8E59-A89CE3F29730Q38220831-CABE70EA-117D-490A-B76A-99AADE056A71Q38620142-E18F5285-01FD-47AD-9BAC-9396C3B2C746Q39781266-1D4A97D7-BAA3-4EB4-B466-5FB064AB04F1Q40092648-8DBDA9EF-7593-4051-9962-2F36B1D87942Q40947235-59454F8F-D843-4B6C-904D-C57D0BAC4244Q41221164-AA78BD2A-4A67-40C6-8841-F3AB366F0B11Q41739223-2E3CB34E-5BE1-4E4C-AA42-EFC9C14FB7AEQ45888265-60FF6999-29E0-44E8-8B63-5AA1BD4186E3Q54083322-48CB4B5F-5AC3-4447-AF4A-D865CE14FA39Q55519151-2D27D22E-6752-4745-AF40-1F4E0BDD3351Q55669829-5190E192-CA6E-44DF-A55A-4A9F1CC78155Q56038581-E2ED2C59-A0E2-47A7-97AD-6323B683FA66
P2860
Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome.
description
1987 nî lūn-bûn
@nan
1987 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Trimetrexate for the treatment ...... red immunodeficiency syndrome.
@ast
Trimetrexate for the treatment ...... red immunodeficiency syndrome.
@en
type
label
Trimetrexate for the treatment ...... red immunodeficiency syndrome.
@ast
Trimetrexate for the treatment ...... red immunodeficiency syndrome.
@en
prefLabel
Trimetrexate for the treatment ...... red immunodeficiency syndrome.
@ast
Trimetrexate for the treatment ...... red immunodeficiency syndrome.
@en
P2093
P1476
Trimetrexate for the treatment ...... red immunodeficiency syndrome.
@en
P2093
Allegra CJ
Chabner BA
Ogata-Arakaki D
Shelhamer JH
Simmons JT
P304
P356
10.1056/NEJM198710153171602
P407
P577
1987-10-01T00:00:00Z